Hung-Ling Wang

Title: **Hung-Ling Wang: Innovator in Immunotherapy**

Introduction

Hung-Ling Wang is a prominent inventor based in New Taipei, Taiwan. He is recognized for his significant contributions to the field of immunotherapy, particularly through his patented innovation that addresses undesirable immune responses.

Latest Patents

Wang holds a patent for "Anti-granulysin antibodies and methods of use thereof." This groundbreaking patent introduces an anti-granulysin antibody that can bind to specific epitope regions of granulysin, effectively neutralizing its activity. The invention may also consist of various antibody fragments, such as scFv or Fab fragments, which allow for a versatile application in treating unwanted immune response disorders like Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or Graft-versus-Host Disease (GVHD). The patent encompasses specific sequences that enhance the effectiveness of these antibodies, showcasing Wang's innovation in improving patient care.

Career Highlights

Hung-Ling Wang has established a significant career within the biotechnology sector. He has been affiliated with the Development Center for Biotechnology, where he contributed to research and development efforts that aim to enhance therapeutic approaches. Additionally, he worked with DCB-USA LLC, further expanding his expertise and impact in the field.

Collaborations

Throughout his career, Wang has collaborated with notable colleagues, including Jiann-Shiun Lai and Chao-Yang Huang. These partnerships have contributed to the advancement of research projects that aim to innovate treatments for complex immune disorders.

Conclusion

Overall, Hung-Ling Wang is a distinguished inventor whose work in anti-granulysin antibodies represents a significant milestone in the field of immunotherapy. His innovative approach and dedication to improving patient outcomes highlight the importance of continued research and development in combating immune response disorders.